CREmedical

Kingston, Rhode Island, USAFounded 20111–10 employeescremedical.com

Brain-computer interfaces
Neuromodulation
EEG and neural monitoring
Neuroscience research tools

CREmedical develops neurotechnology for understanding the brain and researching brain disorders. Its platform combines tripolar concentric ring electrode-based sensing, transcranial focal electrical stimulation, and integrated tEEG+TFS capabilities for brain imaging and neuromodulation research.

Visit cremedical.com ↗

Founded: 2011
Employees: 1–10

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

CREmedical’s documented milestones are concentrated in its early development period rather than in the past six months. The company was founded in 2011 by Walt Besio, whose work underpins its tripolar concentric ring electrode technology. On Dec 18, 2012, CREmedical received a $179,898 grant from the National Science Foundation, followed by a $1,224,712 grant on Sep 5, 2014. Together, these awards total $1,404,610 and represent the company’s last recorded financing activity. Its product portfolio includes t-Leads, tripolar electrodes intended to improve differential EEG signal capture, and the t-Interface 20, which processes electrode signals into tripolar and emulated conventional EEG outputs. Website positioning also identifies an integrated platform combining brain-signal acquisition with transcranial focal electrical stimulation.

Market position

CREmedical operates at the intersection of EEG instrumentation, brain-computer-interface research, and neuromodulation hardware. Its differentiation is technical rather than scale-based: the company focuses on tripolar concentric ring electrodes, tEEG signal acquisition, transcranial focal electrical stimulation, and an integrated tEEG+TFS research workflow. This gives it a more specialized profile than conventional EEG equipment providers centered primarily on recording systems. The t-Leads and t-Interface 20 are designed to work with commonly used amplifier systems and software, which may reduce integration friction for research laboratories and clinical investigators. Its stated use cases include EEG, BCI, seizure detection, brain imaging, and neuromodulation studies. The company’s small reported workforce of one current featured position and its $1.4 million in historical grant funding indicate a focused research-hardware niche rather than a large commercial medtech platform. Competitive strength therefore depends on technical performance, validation, and adoption of its electrode and stimulation architecture.

Growth & opportunities

CREmedical’s trajectory appears to have been shaped by research funding and technology development rather than by a disclosed venture-scale expansion plan. Founded in 2011, the company secured an initial $179,898 National Science Foundation grant on Dec 18, 2012 and a larger $1,224,712 grant on Sep 5, 2014. The second award was roughly 6.8 times the first and brought cumulative recorded funding to $1,404,610, marking the clearest historical inflection point. Its product architecture has expanded beyond individual electrodes: t-Leads provide tripolar sensing, while the t-Interface 20 supports signal processing for both tripolar and emulated conventional EEG. Website materials further describe transcranial focal stimulation and an integrated tEEG+TFS platform, suggesting a progression from sensing hardware toward combined recording and neuromodulation research. There is no disclosed financing after 2014, no reported hiring news, and only one current featured employee position, held by CEO Walt Besio since 2011-02. As a result, current growth, revenue scale, commercialization, and staffing momentum remain difficult to verify.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes CREmedical distinct

reccy insights

What makes CREmedical distinct

01Pioneer of tripolar concentric ring electrodes, designed to improve on conventional electrode configurations.
02Offers an integrated platform combining brain-signal acquisition with focal electrical stimulation.
03Products are compatible with commonly used EEG amplifier systems and software.
04Founded by Walt Besio, the inventor associated with TCRE, tEEG, and TFS technologies.
05Provides configurable research hardware for EEG, BCI, seizure detection, and neuromodulation studies.

Technology & products2

Technology & products

t-Leads
Tripolar electrodes designed to record brain electrical activity using three concentric rings to capture differential signals for improved EEG data.
t-Interface 20
A preamplifier device that processes signals from t-Leads, performing differencing and Laplacian calculations to output both tripolar EEG and emulated conventional EEG signals.

Tripolar Concentric Ring Electrodes (TCREs)
TCRE-based EEG (tEEG)
Transcranial Focal Electrical Stimulation (TFS)
Integrated tEEG+TFS platform
t-Lead TCRE-based sensors
t-Interface 20-channel and 2-channel signal interfaces

Similar companies

Show all 6 companies

About CREmedical

Products: t-Leads, t-Interface 20
Leadership: Walt Besio, CEO
Focus areas: Neurotechnology, BCI, EEG, neuromodulation, medical devices, biomedical engineering, clinical research, research hardware
Headquarters: Kingston, Rhode Island, USA
Founded: 2011
Employees: 1–10